Table 3.

Comparison of METAL and MANTRA results ¹

	METAL		MANTRA
SNP	ORall (95% CI2)	p value	ORAA (95% CrI3)	ORCA (95% CrI)	ORHI (95% CrI)	Log10BF
	Immune-mediated disease
PTPN22 / rs3811021	1.31 (1.10-1.56)	0.003	1.28 (1.03-1.59)	1.31 (1.09-1.57)	1.29 (1.06-1.58)	0.520
male	1.50 (1.15-1.95)	0.003	1.47 (1.04-2.09)	1.50 (1.14-1.96)	1.50 (1.07-2.09)	1.245
female	1.15 (0.90-1.47)	0.260	1.15 (0.88-1.51)	1.16 (0.90-1.49)	1.16 (0.88-1.52)	−0.176
	Autoimmune disease
ARNT / rs11204735	1.29 (1.08-1.55)	0.005	1.30 (1.05-1.62)	1.29 (1.08-1.55)	1.29 (1.06-1.57)	1.064
male	1.35 (0.99-1.85)	0.062	1.38 (0.79-2.40)	1.35 (0.97-1.87)	1.12 (0.41-3.06)	0.153
female	1.30 (1.04-1.62)	0.022	1.30 (1.00-1.70)	1.29 (1.02-1.63)	1.31 (0.99-1.72)	0.490
ARNT / rs1889740	1.25 (1.06-1.47)	0.009	1.23 (1.03-1.48)	1.25 (1.05-1.48)	1.25 (1.04-1.50)	1.000
male	1.38 (1.02-1.86)	0.036	1.45 (0.95-2.21)	1.35 (0.99-1.86)	1.20 (0.44-3.22)	0.488
female	1.24 (1.01-1.52)	0.038	1.22 (0.95-1.55)	1.26 (1.01-1.57)	1.27 (0.98-1.65)	0.545
	Allergic disease
PTPN22 / rs3811021	1.23 (1.03-1.46)	0.023	1.08 (0.73-1.59)	1.28 (1.04-1.57)	1.22 (0.90-1.64)	0.815
male	1.58 (1.20-2.08)	0.001	1.55 (1.11-2.18)	1.59 (1.20-2.09)	1.58 (1.12-2.23)	1.847
female	0.99 (0.78-1.26)	0.936	0.91 (0.61-1.35)	1.02 (0.79-1.32)	1.00 (0.74-1.36)	−0.338

¹Results are from 7-SNP analysis;

²CI = Confidence Interval;

³CrI = Credible Interval

SNP = single nucleotide polymorphism; L95 = Lower boundary of 95% confidence interval; U95 = Upper boundary of 95% confidence interval; OR_all = odds ratio for all groups combined; OR_AA = odds ratio for African American cohort, OR_CA = odds ratio for Caucasian cohort; OR_HI = odds ratio for Hispanic cohort; log₁₀BF = log₁₀ Bayes factor.

The bold entries show results that were significant after Holm-Bonferroni correction (METAL) or credible (Bayesian perspective) considering the upper limit of the log₁₀BF (MANTRA).